The earnings call highlighted significant revenue growth, strong cash position, and progress in vaccine development, suggesting a positive outlook. However, challenges include an operating loss and increased R&D expenses. The sentiment is balanced with a slight positive tilt due to strategic advances.

Company Guidance

During the conference call, Valneva provided comprehensive guidance on several key financial and operational metrics. The company reported a significant year-over-year revenue increase, with total revenues nearing EUR 100 million and a strong cash position exceeding EUR 160 million. Product sales reached EUR 91 million, marking a 33.3% increase compared to the previous year. Valneva confirmed its financial guidance for 2025, projecting product sales between EUR 170 million and EUR 180 million, and total revenues ranging from EUR 180 million to EUR 190 million. The company anticipates research and development expenses to be between EUR 90 million and EUR 100 million, partially offset by grant funding and R&D tax credits. Valneva also highlighted a reduction in operating cash burn and emphasized its strategic focus on maintaining a robust cash position as it progresses with its Lyme disease vaccine VALOR study, with regulatory submissions expected in 2026. The company's gross margin on commercial products, excluding IXCHIQ, improved to 59.2% from 47.7% the previous year, driven by better manufacturing performance.

Significant Revenue Growth

Total revenues reached close to EUR 100 million, marking a 37.8% increase year-over-year, driven by higher product sales and increased licensing revenue from the Serum Institute of India.

Strong Cash Position and Reduced Cash Burn

Cash position exceeded EUR 160 million, with a significant reduction in operating cash burn, indicating efficient investment strategies.

Successful Vaccine Developments

Progress in vaccine programs including Lyme, IXCHIQ, and Shigella with significant milestones such as the lifting of temporary restrictions for IXCHIQ by FDA and EMA.

Product Sales Growth

IXIARO sales increased by 30.6% over the prior year to EUR 54.7 million, and IXCHIQ sales reached EUR 7.5 million from EUR 1 million in the first half of 2024.

Positive Phase III Pediatric Safety and Immunogenicity Results

IXCHIQ showed a high sustained 1-year immune response in adolescents, and positive Phase III pediatric safety and immunogenicity results were achieved.

Valneva (VALN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

VALN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 13, 2025	2025 (Q3)	-0.33 / -	-0.11	―	―	―
Aug 12, 2025	2025 (Q2)	-0.32 / -0.16	-0.383	57.44% (+0.22)
May 07, 2025	2025 (Q1)	-0.34 / -0.14	0.884	-115.84% (-1.02)
Mar 20, 2025	2024 (Q4)	-0.21 / -0.49	-0.509	4.52% (+0.02)
Nov 07, 2024	2024 (Q3)	-0.27 / -0.11	-0.537	79.52% (+0.43)
Aug 13, 2024	2024 (Q2)	-0.34 / -0.38	-0.191	-100.52% (-0.19)
May 07, 2024	2024 (Q1)	1.12 / 0.88	-0.286	409.09% (+1.17)
Mar 20, 2024	2023 (Q4)	0.09 / -0.51	-0.407	-25.06% (-0.10)
Nov 09, 2023	2023 (Q3)	-0.45 / -0.54	1.242	-143.24% (-1.78)
Sep 21, 2023	2023 (Q2)	-0.28 / -0.19	-2.532	92.46% (+2.34)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

VALN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 12, 2025	$8.50	$9.40	+10.59%
May 07, 2025	$6.48	$6.59	+1.70%
Mar 20, 2025	$6.73	$7.25	+7.73%
Nov 07, 2024	$5.59	$5.48	-1.97%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Valneva (VALN) report earnings?

Valneva (VALN) is schdueled to report earning on Nov 13, 2025, TBA (Confirmed).

What is Valneva (VALN) earnings time?

Valneva (VALN) earnings time is at Nov 13, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is VALN EPS forecast?

VALN EPS forecast for the fiscal quarter 2025 (Q3) is -0.33.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing